TECH-INNO Health Participates in Establishing the

"Hot flashes and insomnia starting at 30+? Skin sagging and emotional instability at 40+?" In discussions about women's health, "estrogen" is always a core topic. With increasing health awareness, women's demand for oral health products that regulate estrogen is growing, but the harsh reality is that we have always lacked a truly reliable efficacy evaluation system.

Industry Pain Point: Why are estrogen efficacy claims mostly "conceptual games"?
Many people are confused about estrogen-regulating products: they buy products that claim to "balance hormones," but after several months of use, they feel no effect; different brands make different claims, lacking both a unified evaluation standard and solid scientific evidence.
Behind this is a common problem throughout the industry: traditional cell model experiments are inefficient, and animal experiments are difficult to balance with ethics and stability, leading to many product efficacy claims remaining at the "conceptual level." Consumers find it difficult to distinguish between genuine and false claims, and companies lack clear research and development directions.
The industry urgently needs a scientific, transparent, and practical evaluation system to "safeguard" women's health consumption. Now, this wish has finally become a reality!

Officially Launched! Estrogen Regulation Now Has a "Quantitative Standard"
Recently, under the guidance of the China Chamber of Commerce for Import & Export of Medicines & Health Products, a group standard—"Determination of Estrogen Regulation Efficacy of Oral Health Products—Transgenic Medaka Live Fluorescence Detection Method"—was officially launched, led by Super Yuanliao and jointly participated in by several industry benchmark companies including TECH-INNO Health, Waterstone (International), Bangshang Huachuang, and Food Research Institute FTA!
The technical system of the group standard comes from the domestic estrogen pathway research team—Dr. Chen Xueping's team at Waterstone (International) Biotechnology Co., Ltd.  Their "transgenic medaka fluorescent expression system" method received AOAC International standard approval in 2019 and completed multi-laboratory verification trials, providing a reliable technical baseline and scientific evidence for this standardization path.

This is a specialized evaluation standard for the estrogen regulation efficacy of oral health products, marking the end of the "grey area" in female estrogen regulation efficacy evaluation, and providing clear, reproducible, and quantifiable scientific evidence. The core value of this new set of standards lies in the "live fluorescence detection method for genetically modified medaka fish," which enables the precise quantification of estrogen regulation efficacy. Compared to traditional methods, it not only considers the scientific and ethical aspects of testing but also significantly improves the stability and reliability of the results, ensuring that "efficacy" is no longer just a marketing slogan but verifiable objective data.

This is not TECH-INNO Health's first exploration in the field of efficacy evaluation. As a company deeply rooted in the health industry, TECH-INNO Health has previously established a comprehensive five-dimensional efficacy evaluation system, consistently upholding the principles of science and transparency, and using its professional capabilities to endorse product quality. Participating in the development of this group standard is further proof of the company's commitment to the philosophy of "integrating health better into life."

From single product development to participating in industry standard setting, TECH-INNO Health has always believed that only by establishing a scientific evaluation system can nutritional and health products truly return to their "essential efficacy." We look forward to the early implementation of this group standard, jointly injecting "certainty" into the women's health industry.